secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0000950170-21-004081
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Athira Pharma Q3 net loss $15.7M; ACT-AD trial enrollment completed
-------------------------------------------------------------------

- Net loss of $15.7M ($0.42 per share) vs $8.5M loss in Q3 2020; R&D spend $10.7M.
- Cash, cash equivalents and investments $339.4M as of Sept 30, 2021, up from $268.2M at Dec 31, 2020.
- Completed enrollment in Phase 2 ACT-AD trial (77 subjects); topline data expected H1 2022.
- LIFT-AD Phase 2/3 actively recruiting; topline data expected by end of 2022.
- SHAPE Phase 2 trial (Parkinson's dementia) anticipated to initiate by end of 2021; IND for ATH-1020 expected by end of 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000095017021004081/0000950170-21-004081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000095017021004081/atha-20211110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-004081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer